

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Saxon, et al.

Docket No.:

39754-0672A

Serial No.:

09/847,208

Group Art Unit:

1644

Filing Date:

May 1, 2001

Examiner:

Nuynh, P.

For:

FUSION MOLECULES AND TREATMENT OF IgE-MEDIATED

**ALLERGIC DISEASES** 

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

#### TRANSMITTAL

- Transmitted herewith are the following documents:
  - (1) Transmittal;
  - (2) Supplemental Information Disclosure Statement;
  - (3) PTO Form 1449;
  - (4) Copies of 49 of cited references.
- The Commissioner is authorized to charge any required fees, or credit any overpayment to Deposit Account No. 08-1641.
- Attached is a postcard for date-stamped return as confirmation of receipt of these materials.

Respectfully submitted,

Date: August 14, 2003

Daphne Reddy, Reg. No. 53,50

for

Ginger R. Dreger, Reg. No. 33,055

### HELLER EHRMAN WHITE & MCAULIFFE LLP

Customer No. 25213

275 Middlefield Road

Menlo Park, CA 94025

Telephone: (650) 324-7000

Facsimile: (650) 324-0638

#### CERTIFICATE OF MAILING (37 CFR 1.8(a))

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Mail Stop: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: August 14, 2003

Cheryl Ann Rogers

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Saxon, et al.

Docket No.:

39754-0672A

Serial No.:

09/847,208

Group Art Unit: 1644

Filing Date:

May 1, 2001

Examiner:

Nuynh, P.

For:

FUSION MOLECULES AND T

TREATMENT OF IgE-MEDIATED

**ALLERGIC DISEASES** 

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

cited	in the sta	atement	is, or is considered to be, material to patentability as defined in §1.56.			
	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):					
		(1)	It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  OR			
		(2)	It is being filed within 3 months of entry of a national stage OR			
Service		lass mail i	CERTIFICATE OF MAILING (37 CFR 1.8(a))  aper (along with any referred to as being attached or enclosed) is being deposited with the U.S. Postal  n an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.			

	Ц	(3)	It is being filed before the mail	date of the first Office Action on the merits				
	$\boxtimes$	(4)		ng of a first Office Action after the filing of a on under § 1.114.				
	filing d stage as action of	ate of a rest set forton the m	national application; (2) three mo h in §1.491 in an international ap	ed after the latest of: (1) three months beyond the onths beyond the date of entry of the national oplication; or (3) the mailing date of a first Office of the earlier of a final office action under §1.113				
		a certifi	ication as specified in §1.97(e) is	provided below; or				
			\$180.00 as set forth in \$1.17(p) ment of other papers filed togeth	is authorized below, enclosed, or included with er with this statement.				
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:							
	A.	a certifi	ication as specified in §1.97(e) is	completed below; and				
	В.		on under 37 C.F.R. §1.97(d) required herewith; and	esting consideration of this statement is				
	C.		\$180.00 as set forth in \$1.17(i)(ment of other papers filed togeth	1) is authorized below, enclosed, or included with er with this statement.				
	Fee Authorization. The Commissioner is authorized to charge any required fees, additional fees, or credit any overpayment to Deposit Account 08-1641 (Docket No. 39754-0672A).							
				Respectfully submitted,				
Dated:	August	12, 2003	3	By: (1) (2)				
		-, ·		Ginger R. Dreger Reg. No. 33,055				
				0				

HELLER EHRMAN WHITE & MCAULIFFE LLP

Customer No. 25213 275 Middlefield Road

Menlo Park, CA 94025-3506 Telephone: (650) 324-7000

Facsimile: (650) 324-0638

STATEMENO STATEMENO			ATTY. DOCKET NO.: 39754-0672	1	SERIAL NO.: 09/847,208			
PTO-1449 AUG 1 8 APPLICANT: Saxon et al.								
All V			FILING DATE: May 1, 2001		GROUP: 1644			
	(N)	Va married U.S.	PATENT DOCUMENTS	<del></del>		<del></del>		
EXAMINER'S INITIALS	EXAMINER'S PATENT NO. DATE		NAME	CLASS	SUBCLASS	FILING DATE		
	20030049237	3/13/03	Bannon, Gary A., et al.					
	20010053770	12/20/01	Thomas, David, et al.					
	20030077282	4/24/03	Bigler, Michael Eric, et al.					
	6,043,345	3/28/00	Saxon, et al.					
	5,563,250	5/13/94	Hylarides, Mark D., et al.					
	5,827,516	6/7/95	Urban, Robert Glen, et al.					
	5,811,265	7/26/93	Quertermous, Thomas, et al.					
	6,093,699	11/10/94	Sehon, Alec, et al.					
	5,965,605	10/12/99	Cheng, et al.					
	5,017,693	12/19/89	Hylarides, Mark D., et al.					
		FORE	LIGN PATENT DOCUMENTS	<del>,</del>		<del>,</del>		
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	YES	LATION NO	
	WO 96/12740	05/02/96	EP	<del> </del>				
	WO 95/26365	10/5/95	EP	<del> </del>	ļ			
	WO 93/20303	10/3/93	LI	<del></del>	<del> </del>			
			<del> </del>	<del> </del>			<u> </u>	
				L	F( )	L	L	
	Abdelilah, S.G.,	et al., "Moleci	Including Author, Title, Date, Pular Characterization of the Low- nils", Int. Immunol., 1998 Apr; 10	Affinity Igl	E Receptor FceR	II/CD23		
			en immunotherapy for asthma", 7	<del></del>		lan 1·1	-32	
	<del> </del>	<del></del>	<del></del>					
-	Akdis, Cezmi A., et al., "Epitope-specific T Cell Tolerance to Phospholipase A <sub>2</sub> in Bee Venom Immunotherapy and Recovery by IL-2 and IL-15 In Vitro", <i>The American Society for Cinical Investigations, Inc.</i> , 1996, Oct; 98(7):1676-1683.							
	Brazís, P., et al., "Stem Cell Factor Enhances IgE-Mediated Histamine and TNF-α Release From Dispersed Canine Cutaneous Mast Cells", Vet Immunol. Immunopathol, 2000 Jun 30; 75(1-2):97-108.						spersed	
	Campbell, K.A., "Co-Crosslinking FceRII/CD23 and B cell Surface Immunoglobulin Modulates B Cell Activation", Eur J. Immuno.l 1992 Aug; 22(8):2107-12.						Cell	
EXAMINER	EXAMINER DATE CONSIDERED							

		SHEET 2 OF						
INFORMATION DISCLASTEE	ATTY. DOCKET NO.:	SERIAL NO.:						
STATEMENTO	39754-0672	09/847,208						
PTO-1449 AUG 1 8 7003	APPLICANT: Saxon et al.							
P. Auto	FILING DATE: May 1, 200	1						
OTHER DOCUMENTS	(Including Author, Title, Date, Po	ertinent Pages, Etc.)						
Castells, M., "Mast Cells: Mo Vøl1N1:1-17, 1999.	Castells, M., "Mast Cells: Molecular and Cell Biology", The Journal of Asthma, Allergy and Immunology,							
Delespesse, G., et al., "The Lo	Delespesse, G., et al., "The Low-Affinity Receptor for IgE", Immunol Rev. 1992 Feb;125:77-97.							
Daeron, Marc., "FcγRIIB as Potential Therapeutic Targets for Allergic Diseases", presented at the A Meeting of the American Academy of Allergy, Asthma & Immunology, March 16-21, New Orleans,								
	Guo, C.B., et al., "Identification of IgE-bearing Cells in the Late-phase Response to Antigen in the Lung as Basophils", Am J Respir. Cell Mol. Biol., 1994 Apr; 10(4):384-90.							
Henz, B.M., et al., "[Urticaria	. New developments and perspect	ves]., Hautarzt 2000 May;51(5):302-8.						
Hulett, Mark D., et al., "Fine Chemistry, Vol. 274, No. 19:1		f Fc∈RI with IgE", Journal of Biological						
Kawabori, S., et al., "Existence of c-kit Receptor-Positive, Tryptase-Negative, IgE-Neg Cells in Hum Allergic Nasal Mucosa: A Candidate for Mast Cell Progenitor", Int. Arch Allergy Immunol. 1997 Jan;112:36-43.								
Kepley, C.L., et al., "Purificat 175:1-9, 1994.	Kepley, C.L., et al., "Purification of Human Basophils by Density and Size Alone", J. Immunol. Meth., 175:1-9, 1994.							
Kepley, C.L., et al., "The Identification and Partial Characterization of a Unique Marker for Human Başophils", J. Immunol., 154, 6548-6555, 1995.								
* - * ·	Kepley, C.L., et al., "The Identification and Characterization of Umbilical Cord-Blood Derived Basophils", J. Leukocyte Biol., 64:474-483, 1998.							
Kikutani, H., et al., "Molecula 1986 Dec 5;47(5):657-65.	ar Structure of Human Lymphocyto	Receptor for Immunoglobulin E", Cell						
		Regulate Immunoreceptor-dependent Cell 45, Issue of November 5, pp. 32493-32499,						
Lin, Shih-Yao, et al., "Giving 445-446, 2001.	Inhibitory Receptors a Boost", Sci	ence, Vol. 291, Issue of January 19, pp.						
Dermatophagoides pteronyssi	ant Reduction of Nonspecific Bron inus-sensitive Allergic Asthma und Dis., Vol. 147, pp. 1407-1412, 19	ler Therapy with Allergen-Antibody						
		specific Antibodies Reduce Allergic Clin. Exp. Allergy, Nov 20(6); 653-60,						
	n-Antibody Complexese Can Effic resensitive Patients", Allergy, 1991,	iently Prevent Seasonal Rhinitis and 46, 335-348.						
XAMINER	DATE CONSIDERED							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

AND 1 STORM TO AND INFORM

# INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.:

**SERIAL NO.:** 

39754-0672

09/847,208

PTO-1449

APPLICANT: Saxon et al.

FILING DATE: May 1, 2001

**GROUP: 1644** 

#### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Machiels, J.J., et al., "Allergic Brochial Asthma Due to Dermatophagoides pteronyssinus Hypersensitivty Can Be Efficiently Treated by Inoculation of Allergen-Antibody Complexes", J. Clin. Invest., Vol. 85, April 1990, 1024-1035.

Metcalfe, D.D., et al., "Mast Cell Ontogeny and Apoptosis", Exp. Dermatol. 1995: 4:227-230.

Milgrom, H., et al., "Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody", The New England Journal of Medicine, Vol. 341, No. 26, 1966-1973, 1999.

Nakagawa, T., et al., "Immunotherapy of Allergic Diseases", Int. Arch. Allergy Immunol 102(2):117-20 1993.

oliver, Janet M., et al., "Immunologically Mediated Signaling in Basophils and Mast Cells: Finding Therapeutic Targets for Allergic Diseases in the Human FceR1 Signaling Pathway", *Immunopharmacology* 48, 269-281, 2000.

OSborne, Mark A., et al., "The Inositol 5'-Phosphatase SHIP Binds to Immunoreceptor Signaling Motifs and Responds to High Affinity IgE Receptor Aggregation", *The Journal of Biological Chemistry*, Vol. 271, No. 46, Issue of November 15, pp. 29271-29278, 1998.

Fivnyuk, V. I., et al., "Human Low-Affinity IgE Receptor: cDNA from Cell Line 1B and Its Expression in Peripheral Blood Cells", translated from *Molekulyarnaya Biologiya*, Vol 28, No. 1, pp. 840-845, July-August, 1994.

Schwartz., L., et al., "Development of Markers for Human Basophils and Mast Cells", J. Allergy and Clin. Immunol., Vol. 94, No. 6, pp 1231-1240, 1994.

Sinclair, N.R. StC., "Why So Many Coinhibitory Receptors?", Scand. J. Immunol. 50, 1-13, 1999.

Suter, U., et al., "Expression of Human Lymphocyte IgE Receptor (Fc<sub>e</sub>RII/CD23). Identification of the Fc<sub>e</sub>RIIa Promoter and Functional Analysis in B Lymphocytes", J. Immunol. Nov 1; 143(9):3087-92, 1989.

Wang, M., et al., "Early IL-4 Production Driving Th2 Differentiation in a Human in Vivo Allergic Model is Mast Cell Derived", Clin. Immunol. Jan;90(1):47-54, 1999.

Yabuuchi, Shingo, et al., "Anti-CD23 Monoclonal Antibody Inhibits Germline C∈ Transcription in B Cells", International Immunopharmacology 2, 453-461, 2002.

Yamashita, T., et al., "Expression Cloning of Complementary DNA Encoding Three Distinct Isoforms of Guinea Pig Fc Receptor for IgG1 and IgG2<sup>1</sup>", J. Immunol. Aug 15;151(4) pp. 2014-2023, 1993.

Yamashita, Y., et al., "Inhibitory and Stimulatory Functions of Paired Ig-Like Receptor (PIR) Family in RBL-2H3 Cells<sup>1</sup>", *The Journal of Immunology*, 1998, 161: 4042-4047.

van Rossenberg, S.M., et al., "Ligand Recognition by CD22 {beta}: A Structure Function Study", J. Biol. Chem Jan 4, 2001.

Zhu, Daocheng, et al., "A Novel Human Immunoglobulin Fcγ-Fcε Bifunctional Fusion Protein Inhibits FcεRI-Mediated Degranulation", *Nature Medicine* Vol. 8, No. 5, pp. 518-521, May 2002.

**EXAMINER** 

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.